Westbrook, Thomas C.
Guan, Xiangnan
Rodansky, Eva
Flores, Diana
Liu, Chia Jen
Udager, Aaron M.
Patel, Radhika A.
Haffner, Michael C.
Hu, Ya-Mei http://orcid.org/0000-0002-2575-1770
Sun, Duanchen
Beer, Tomasz M. http://orcid.org/0000-0001-5600-9993
Foye, Adam
Aggarwal, Rahul http://orcid.org/0000-0001-7003-7982
Quigley, David A.
Youngren, Jack F.
Ryan, Charles J.
Gleave, Martin
Wang, Yuzhuo http://orcid.org/0000-0002-9749-8591
Huang, Jiaoti http://orcid.org/0000-0003-1195-1998
Coleman, Ilsa
Morrissey, Colm
Nelson, Peter S. http://orcid.org/0000-0002-5451-5726
Evans, Christopher P.
Lara, Primo
Reiter, Robert E.
Witte, Owen
Rettig, Matthew
Wong, Christopher K. http://orcid.org/0000-0001-6012-7001
Weinstein, Alana S. http://orcid.org/0000-0002-1563-9072
Uzunangelov, Vlado http://orcid.org/0000-0002-1962-0977
Stuart, Josh M. http://orcid.org/0000-0002-2171-565X
Thomas, George V. http://orcid.org/0000-0001-7416-8840
Feng, Felix Y. http://orcid.org/0000-0002-0963-7687
Small, Eric J. http://orcid.org/0000-0003-3191-6268
Yates, Joel A. http://orcid.org/0000-0002-1462-8494
Xia, Zheng http://orcid.org/0000-0003-3364-8324
Alumkal, Joshi J. http://orcid.org/0000-0003-1278-0166
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Cancer Institute (T32 CA009357, P50 CA186786, P50 CA097186, P50 CA097186, SU2C-AACR-DT0409, P01 CA163227, U54 CA224079, R01 CA251245, P50 CA097186, P50 CA186786, CA186786-07S1, P30 CA046592)
U.S. Department of Health & Human Services | NIH | National Cancer Institute
U.S. Department of Health & Human Services | NIH | National Cancer Institute
Doris Duke Charitable Foundation (Grant 2021184)
V Foundation for Cancer Research
EIF | Stand Up To Cancer (SU2C-AACR-DT0409, SU2C-AACR-DT0409, SU2C-AACR-DT0409, SU2C-AACR-DT0409, SU2C-AACR-DT0409, SU2C-AACR-DT0409, SU2C-AACR-DT0409, SU2C-AACR-DT0409, SU2C-AACR-DT0409, SU2C-AACR-DT0409, SU2C-AACR-DT0409, SU2C-AACR-DT0409, SU2C-AACR-DT0409)
U.S. Department of Health & Human Services | NIH | National Cancer Institute
U.S. Department of Health & Human Services | NIH | National Cancer Institute
U.S. Department of Health & Human Services | NIH | National Cancer Institute
U.S. Department of Health & Human Services | NIH | National Cancer Institute
U.S. Department of Defense (W81XWH2110539, W81XWH-20-1-0405)
Prostate Cancer Foundation (Challenge Award)
U.S. Department of Health & Human Services | NIH | National Cancer Institute
U.S. Department of Health & Human Services | NIH | National Cancer Institute
U.S. Department of Health & Human Services | NIH | National Cancer Institute
U.S. Department of Health & Human Services | NIH | National Cancer Institute
U-M | University of Michigan Comprehensive Cancer Center (Innovation Award)
U.S. Department of Health & Human Services | NIH | National Cancer Institute
National Comprehensive Cancer Network/Astellas Pharma Global Development Award the Sheppard Family Fund
Article History
Received: 14 March 2022
Accepted: 11 August 2022
First Online: 15 September 2022
Competing interests
: O. Witte currently has consulting, equity, and/or board relationships with Trethera Corporation, Kronos Biosciences, Sofie Biosciences, Breakthrough Properties, Vida Ventures, Nammi Therapeutics, Two River, Iconovir, Appia BioSciences, Neogene Therapeutics, 76Bio, and Allogene Therapeutics outside of submitted work. T.M. Beer reports consulting fees from AbbVie, Arvinas, Astellas Pharma, AstraZeneca, Bayer, Constellation, Grail Inc., Janssen, Myovant Sciences, Pfizer, Sanofi, Sapience Therapeutics, Bristol-Myers Squib, Novartis, Clovis Oncology, stock ownership in Arvinas Inc, Salarius Pharmaceuticals and researching funding from Alliance Foundation Trials, Astellas Pharma, Bayer, Boehringer Ingelheim, Corcept Therapeutics, Endocyte Inc./Advanced Accelerator Applications (AAA), Freenome, Grail Inc., Harpoon Therapeutics, Janssen Research & Development, Medivation Inc., Sotio, Theraclone Sciences/OncoResponse, Zenith Epigenetics, all outside of submitted work. J. Alumkal has received consulting and speaker’s fees from Astellas Pharma, consulting fees from Dendreon, consulting fees from Merck, consulting fees from Bristol Myers Squibb, and research support to his institution from Astellas Pharma, Zenith Epigenetics, and Beactica. The remaining authors declare no conflicts of interest.